Technical Analysis for LMNL - Liminal BioSciences Inc.

Grade Last Price % Change Price Change
F 3.97 1.02% 0.04
LMNL closed up 3.42 percent on Wednesday, April 21, 2021, on 24 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 1
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical LMNL trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 1.02%
Oversold Stochastic Weakness 1.02%
MACD Bearish Signal Line Cross Bearish 4.47%
Lizard Bullish Bullish Day Trade Setup 4.47%
Bollinger Band Squeeze Range Contraction 4.47%
Doji - Bullish? Reversal 4.47%
Lower Bollinger Band Walk Weakness 4.47%
Stochastic Reached Oversold Weakness 4.47%
BB Squeeze + Lower Band Touch Range Contraction 4.47%
Below Lower BB Weakness 4.47%
Older End-of-Day Signals for LMNL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 2 hours ago
60 Minute Opening Range Breakout about 3 hours ago
Up 3% about 3 hours ago
Up 2% about 5 hours ago
Rose Above Previous Day's High about 5 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Liminal BioSciences Inc. Description

Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Drug Discovery Molecular Biology Manufacturing Process Manufacturing Processes Blood Plasma Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Molecule Therapeutics Pharmaceutical And Medical Treatment Of Idiopathic Pulmonary Fibrosis Alpha 1 Antitrypsin Drug Discovery Platform Genetically Modified Organism Protein Purification

Is LMNL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.45
52 Week Low 3.51
Average Volume 417,801
200-Day Moving Average 7.58
50-Day Moving Average 4.64
20-Day Moving Average 4.11
10-Day Moving Average 4.12
Average True Range 0.27
ADX 17.66
+DI 18.25
-DI 27.81
Chandelier Exit (Long, 3 ATRs ) 3.80
Chandelier Exit (Short, 3 ATRs ) 4.42
Upper Bollinger Band 4.44
Lower Bollinger Band 3.79
Percent B (%b) 0.22
BandWidth 15.87
MACD Line -0.15
MACD Signal Line -0.14
MACD Histogram -0.0102
Fundamentals Value
Market Cap 115.49 Million
Num Shares 29.4 Million
EPS -12.81
Price-to-Earnings (P/E) Ratio -0.31
Price-to-Sales 36.00
Price-to-Book 4.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.15
Resistance 3 (R3) 4.14 4.05 4.12
Resistance 2 (R2) 4.05 3.99 4.06 4.10
Resistance 1 (R1) 3.99 3.96 4.02 4.00 4.09
Pivot Point 3.90 3.90 3.92 3.91 3.90
Support 1 (S1) 3.84 3.84 3.87 3.86 3.77
Support 2 (S2) 3.75 3.81 3.76 3.76
Support 3 (S3) 3.69 3.75 3.74
Support 4 (S4) 3.71